{"id":"NCT05568797","sponsor":"GlaxoSmithKline","briefTitle":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","officialTitle":"A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of an RSVPreF3 OA Investigational Vaccine When Co-administered With FLU aQIV (Inactivated Influenza Vaccine - Adjuvanted) in Adults Aged 65 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-10-14","primaryCompletion":"2023-02-17","completion":"2023-07-17","firstPosted":"2022-10-06","resultsPosted":"2024-03-15","lastUpdate":"2024-09-24"},"enrollment":1045,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"RSVPreF3 OA vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"FLU vaccine","otherNames":["Fluad Tetra, FLUAD QUADRIVALENT, Fluad Quad"]}],"arms":[{"label":"Co-Ad Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU aQIV) vaccine, in adults aged 65 years of age (YOA).","primaryOutcome":{"measure":"Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose","timeFrame":"At 1 month after the FLU vaccine dose (Day 31 for both groups)","effectByArm":[{"arm":"Co-Ad Group","deltaMin":43.8,"sd":null},{"arm":"Control Group","deltaMin":57.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":37,"countries":["Belgium","Finland","France","Spain","United Kingdom"]},"refs":{"pmids":["39099085"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":523},"commonTop":["Injection site pain","Fatigue","Myalgia","Headache","Arthralgia"]}}